Qiagen (NYSE:QGEN) Earns Equal Weight Rating from Morgan Stanley

Morgan Stanley reiterated their equal weight rating on shares of Qiagen (NYSE:QGEN) in a research note published on Monday morning, MarketBeat.com reports. The firm currently has a $48.00 price objective on the stock, down from their prior price objective of $50.00.

A number of other research analysts have also recently weighed in on the stock. Jefferies Financial Group reiterated a “buy” rating and set a $54.00 price objective (up previously from $42.00) on shares of Qiagen in a research report on Tuesday, December 10th. HSBC downgraded shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a report on Thursday, October 17th. Finally, Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research note on Thursday, October 17th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $51.50.

Qiagen Price Performance

Shares of Qiagen stock opened at $45.23 on Monday. The stock has a 50 day moving average price of $43.88 and a 200-day moving average price of $43.86. Qiagen has a one year low of $39.03 and a one year high of $47.44. The stock has a market cap of $10.32 billion, a price-to-earnings ratio of 115.97, a price-to-earnings-growth ratio of 3.52 and a beta of 0.37. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of QGEN. Wellington Management Group LLP raised its holdings in shares of Qiagen by 77.7% in the 3rd quarter. Wellington Management Group LLP now owns 21,250,943 shares of the company’s stock valued at $963,386,000 after purchasing an additional 9,293,040 shares in the last quarter. Barclays PLC raised its stake in Qiagen by 170.6% in the third quarter. Barclays PLC now owns 1,849,004 shares of the company’s stock worth $84,259,000 after buying an additional 1,165,594 shares in the last quarter. Victory Capital Management Inc. raised its stake in Qiagen by 62.6% in the third quarter. Victory Capital Management Inc. now owns 2,574,705 shares of the company’s stock worth $117,329,000 after buying an additional 991,325 shares in the last quarter. Nuance Investments LLC lifted its holdings in Qiagen by 17.3% during the second quarter. Nuance Investments LLC now owns 5,271,494 shares of the company’s stock worth $216,606,000 after buying an additional 778,005 shares during the period. Finally, Point72 Asset Management L.P. boosted its position in Qiagen by 148.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,184,806 shares of the company’s stock valued at $48,684,000 after acquiring an additional 708,533 shares in the last quarter. Institutional investors own 70.00% of the company’s stock.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.